Founded in 2009 by pioneers in biopharmaceuticals, Renova Therapeutics is working to create a portfolio of gene therapies to restore health to people suffering from cardiovascular and metabolic diseases. The company’s first targets are gene therapies for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world.
Our investigational gene therapies are based on carefully validated and proprietary research into disease mechanisms and the founders’ nearly 50 combined years of work in the gene therapy field. This experience forms the basis of the company’s efforts to generate an entirely original platform of therapeutics and delivery systems that may provide durable, life-long treatments for chronic diseases.
We believe that by making our gene widely accessible, we can help renew millions of lives and positively impact rising health care costs.
- Our mission: Creating transformational gene therapies that treat the most debilitating and pervasive diseases to restore health and renew life.